Hubbry Logo
HydralazineHydralazineMain
Open search
Hydralazine
Community hub
Hydralazine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hydralazine
Hydralazine
Hydralazine
View on Wikipedia
from Wikipedia

Hydralazine
Skeletal formula of hydralazine
Ball-and-stick model of the hydralazine molecule
Clinical data
Trade namesApresoline, BiDil, others
AHFS/Drugs.comMonograph
MedlinePlusa682246
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability26–50%
Protein binding85–90%
MetabolismLiver
Onset of action5–30 minutes[2]
Elimination half-life2–8 hours, 7–16 hours (renal impairment)
Duration of action2–6 hours[2]
ExcretionUrine
Identifiers
  • 1-hydrazinylphthalazine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.001.528 Edit this at Wikidata
Chemical and physical data
FormulaC8H8N4
Molar mass160.180 g·mol−1
3D model (JSmol)
  • NNc1c2ccccc2cnn1
  • InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12) checkY
  • Key:RPTUSVTUFVMDQK-UHFFFAOYSA-N checkY
  (verify)

Hydralazine, sold under the brand name Apresoline among others, is a medication used to treat high blood pressure and heart failure.[2] This includes high blood pressure in pregnancy and very high blood pressure resulting in symptoms.[3] It has been found to be particularly useful in heart failure, together with isosorbide dinitrate, for treatment of people of African descent.[2] It is given by mouth or by injection into a vein.[3] Effects usually begin around 15 minutes and last up to six hours.[2]

Common side effects include headache and fast heart rate.[2] It is not recommended in people with coronary artery disease or in those with rheumatic heart disease that affects the mitral valve.[2] In those with kidney disease a low dose is recommended.[3] Hydralazine is in the vasodilator family of medications, so it is believed to work by causing the dilation of blood vessels.[2]

Hydralazine was discovered while scientists at Ciba were looking for a treatment for malaria.[4] It was patented in 1949.[5] It is on the World Health Organization's List of Essential Medicines.[6] In 2023, it was the 109th most commonly prescribed medication in the United States, with more than 6 million prescriptions.[7][8]

Medical use

[edit]

Hydralazine is not used as a primary drug for treating hypertension because it elicits a reflex sympathetic stimulation of the heart (the baroreceptor reflex).[9] The sympathetic stimulation may increase heart rate and cardiac output, and in people with coronary artery disease may cause angina pectoris or myocardial infarction.[10] Hydralazine may also increase plasma renin concentration, resulting in fluid retention. To prevent these undesirable side effects, hydralazine is usually prescribed in combination with a beta blocker (e.g., propranolol) and a diuretic.[10]

Hydralazine is used to treat severe hypertension, but is not a first-line therapy for essential hypertension. Hydralazine is often used to treat hypertension in pregnancy together with either labetalol and/or methyldopa.[11]

Hydralazine is commonly used in combination with isosorbide dinitrate for the treatment of congestive heart failure in black populations. This preparation, isosorbide dinitrate/hydralazine, was the first race-based prescription drug.[12]

It should not be used in people who have tachycardia, heart failure, constrictive pericarditis, lupus, a dissecting aortic aneurysm, or porphyria.[13]

Adverse effects

[edit]

Prolonged treatment may cause a syndrome similar to lupus, which can become fatal if the symptoms are not noticed and drug treatment stopped.[13] Hydralazine is within the top three drugs that is known to induce systemic lupus and this adverse drug event is dose dependent yet significant.

Very common (>10% frequency) side effects include headache, tachycardia, and palpitations.[13]

Common (1–10% frequency) side effects include flushing, hypotension, anginal symptoms, aching or swelling joints, muscle aches, positive tests for atrial natriuretic peptide, stomach upset, diarrhea, nausea and vomiting, and swelling (sodium and water retention).[13]

Interactions

[edit]

Hydralazine may potentiate the antihypertensive effects of:[13]

Drugs subject to a strong first-pass effect, such as beta blockers, may increase the bioavailability of hydralazine.[13] The heart rate-accelerating effects of epinephrine (adrenaline) are increased by hydralazine, and coadministration may lead to toxicity.[13]

Mechanism of action

[edit]

Hydralazine is a direct-acting smooth muscle relaxant and acts as a vasodilator primarily in resistance arterioles, also known as the smooth muscle of the arterial bed. The molecular mechanism involves inhibition of inositol trisphosphate-induced Ca2+ release from the sarcoplasmic reticulum in arterial smooth muscle cells.[14][15] By relaxing vascular smooth muscle, vasodilators act to decrease peripheral resistance, thereby lowering blood pressure and decreasing afterload.[10] The exact mechanism of action of hydralazine is unknown, at least as of 1981.[16]

Metabolic products include the N-acetyl derivative, pyruvic acid hydrazone, and acetone hydrazone, each of which may also contribute to reducing blood pressure.[17]

Chemistry

[edit]

Hydralazine belongs to the hydrazinophthalazine class of drugs.[18]

History

[edit]

The antihypertensive activity of hydralazine was discovered by scientists at Ciba, who were trying to discover drugs to treat malaria; it was initially called C-5968 and 1-hydrazinophthalazine; Ciba's patent application was filed in 1945 and issued in 1949,[19][20][21] and the first scientific publications of its blood pressure-lowering activities appeared in 1950.[4][18][22] It was approved by the FDA in 1953.[23]

It was one of the first antihypertensive medications that could be taken by mouth.[9]

Research

[edit]

Hydralazine has also been studied as a treatment for myelodysplastic syndrome in its capacity as a DNA methyltransferase inhibitor.[24]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Hydralazine

View on Grokipedia
from Grokipedia
Hydralazine is a hydrazine-derived direct-acting vasodilator primarily used to treat and as adjunctive therapy in . It functions by relaxing arteriolar through interference with calcium influx and possibly other mechanisms, thereby reducing peripheral and lowering without significant venodilation. Originally synthesized in the and investigated as an antimalarial agent, hydralazine was repurposed for antihypertensive use after demonstrating marked vasodilatory effects, receiving FDA approval in 1953. Administered orally for chronic management or intravenously for acute hypertensive emergencies, including in pregnancy-associated , it remains relevant despite newer agents due to its rapid onset and specificity for arterial beds. However, long-term high-dose therapy is notably associated with autoimmune toxicities, such as and antineutrophil cytoplasmic antibody (ANCA)-positive , affecting a subset of patients and necessitating monitoring for arthralgias, rash, and serological changes.

Medical Uses

Treatment of Hypertension

Hydralazine is utilized orally for the treatment of , functioning as monotherapy or an adjunct to other antihypertensive agents. Typical initial dosing begins at 10 mg four times daily for the first 2 to 4 days, escalating to 25 mg four times daily, with maintenance doses ranging from 50 to 100 mg per day administered in two to four divided doses; maximum daily intake should not exceed 300 mg. The drug achieves reduction primarily through selective arteriolar , which lowers systolic and diastolic pressures, though this effect is often accompanied by reflex tachycardia necessitating with beta-blockers to mitigate compensatory increases in and preserve efficacy. Clinical trials indicate modest lowering, with mean reductions of approximately 10-15 mm Hg systolic and 8-10 mm Hg diastolic in patients with primary compared to , based on before-and-after studies of limited methodological quality. Response rates in historical controlled trials for monotherapy range from 50% to 70% of patients achieving target reductions, though contemporary guidelines position hydralazine as a less preferred option due to its side effect profile and the availability of agents with more favorable tolerability and once-daily dosing. It remains relevant for resistant cases where other therapies prove inadequate.

Management of Heart Failure

Hydralazine is used in the management of with reduced (HFrEF), primarily in combination with as a vasodilator added to standard treatments such as beta-blockers, inhibitors, or ARNI when further optimization is needed. The combination, commercially available as BiDil, targets arterial and venous dilation to reduce cardiac workload. In the V-HeFT I trial conducted from 1980 to 1985, hydralazine plus added to digoxin and diuretics reduced all-cause mortality by 34% over ( 0.66; 95% CI 0.50-0.86) in 459 patients with moderate to severe , establishing it as the first vasodilator regimen to demonstrate a survival benefit. Subgroup analyses indicated greater relative mortality reductions in African American participants compared to white participants. The African-American Trial (A-HeFT), published in 2004, specifically enrolled 1,050 self-identified patients with NYHA class III or IV HFrEF on optimal standard therapy and randomized them to hydralazine-isosorbide dinitrate or . The trial demonstrated a 43% relative reduction in the composite endpoint of all-cause mortality or first hospitalization (6.2% vs. 10.2% mortality alone; 0.58; 95% CI 0.39-0.88), prompting early termination for and leading to FDA approval of BiDil in 2005 for this population. These benefits were attributed to enhanced in populations with potential deficiencies, though generalizability remains limited outside African American cohorts due to underrepresentation in trials and inconsistent benefits in broader studies like V-HeFT II, where enalapril outperformed the combination overall. Current guidelines from the / recommend the combination for self-identified patients with persistent NYHA III-IV symptoms despite guideline-directed therapy. Mechanistically, hydralazine acts as a direct arterial vasodilator, reducing by approximately 34% and thereby decreasing , which enhances and by up to 58% without significantly affecting preload when combined with dinitrate's venodilatory effects. This reduction improves left ventricular and exercise tolerance in HFrEF, as evidenced by hemodynamic improvements in early studies. However, therapy requires monitoring for nitrate tolerance, , and fluid retention, which can offset benefits if not managed with concomitant standard therapies. Long-term use is generally reserved for cases intolerant to ACE inhibitors, ARBs, or , given superior outcomes with those agents in diverse populations.

Use in Hypertensive Emergencies and Pregnancy

Hydralazine is employed intravenously in hypertensive emergencies to facilitate controlled reduction in patients with acute end-organ damage, such as or acute . Administered as 5-10 mg boluses over 1-2 minutes, it exhibits an within 10-20 minutes and a duration of 1-4 hours, allowing for titratable primarily affecting arterioles. Guidelines emphasize gradual reduction of 20-25% within the first hour to mitigate risks of cerebral hypoperfusion, with repeat dosing every 20-30 minutes as needed until stabilization, though its hypotensive response can be unpredictable and requires close monitoring. In pregnancy, particularly for managing severe in or , intravenous hydralazine serves as a first-line agent per American College of Obstetricians and Gynecologists (ACOG) recommendations, often alongside for seizure prophylaxis. Dosing typically starts at 5-10 mg IV every 20-40 minutes, with a maximum of 20 mg per dose, aiming to lower severe-range s (systolic ≥160 mmHg or diastolic ≥110 mmHg) while preserving uteroplacental . It is considered safe for use in the second and third trimesters, with established efficacy in reducing maternal without significant fetal compromise when fetal monitoring is maintained continuously due to risks of maternal . Hydralazine's selection in obstetric scenarios may circumvent beta-blocker contraindications, such as in cases of fetal or maternal , providing an alternative direct vasodilator option.

Pharmacology

Mechanism of Action

Hydralazine primarily induces by directly relaxing arteriolar , selectively targeting resistance vessels to reduce total peripheral resistance while exerting minimal effects on venous . This arteriolar specificity minimizes reductions in venous return and preload, distinguishing it from venodilators like nitrates. At the cellular level, hydralazine disrupts in vascular cells, inhibiting Ca²⁺-dependent activity and processes essential for contraction, with half-maximal inhibition observed at concentrations around 2 × 10⁻⁵ M in biochemical assays. It also suppresses (IP₃)-induced calcium release from stores and interferes with extracellular calcium influx, collectively diminishing the cytosolic calcium levels required for myosin light chain and cross-bridge formation. Hydralazine further promotes hyperpolarization by activating high conductance Ca²⁺-activated potassium channels (BK_Ca), which increases potassium efflux, stabilizes the , and reduces the opening probability of voltage-gated calcium channels, thereby reinforcing relaxation. This channel modulation has been demonstrated in isolated vascular preparations where hydralazine's effects persist despite blockers of other pathways. Empirical in vitro studies on endothelium-denuded arterial rings confirm that hydralazine's relaxation occurs via -independent intracellular mechanisms in , such as direct inhibition of calcium mobilization, setting it apart from endothelium-dependent vasodilators. While some vasodilatory contributions may involve enhanced endothelial bioavailability in intact vessels, the core arteriolar action relies on -autonomous pathways supported by biochemical and electrophysiological data.

Pharmacokinetics and Pharmacodynamics

Hydralazine is rapidly absorbed from the after , achieving peak plasma concentrations within 1 hour, though its is reduced to 30-50% in slow acetylators and 22-30% in rapid acetylators due to extensive first-pass in the intestinal mucosa and liver. Intravenous administration bypasses absorption limitations, providing complete and onset within 5-30 minutes for acute settings. The drug is widely distributed throughout the body, with protein binding of 85-90%. Metabolism occurs primarily via N-acetylation in the liver, governed by polymorphic activity of N-acetyltransferase 2 (NAT2), resulting in slow or rapid acetylator phenotypes that influence plasma exposure; slow acetylators, more prevalent in Caucasian populations, attain higher hydralazine concentrations, enhancing efficacy but elevating risks like drug-induced . Elimination varies from 2-8 hours in individuals with normal renal function, extending to 7-16 hours in renal impairment, with clearance predominantly extrahepatic (55% in rapid acetylators, 70% in slow); unmetabolized drug and acetylated metabolites are excreted mainly in urine. for NAT2 status can guide dosing to mitigate variability in steady-state levels. Pharmacodynamically, hydralazine's arteriolar produces a short duration of effect (2-6 hours), requiring divided oral dosing (typically 2-4 times daily) to sustain antihypertensive action at . Reflex tachycardia, mediated by baroreceptor activation in response to the precipitous drop, emerges dose-dependently and correlates with the acute pharmacokinetic peak, often necessitating co-administration with beta-blockers to optimize hemodynamic tolerance. This kinetic-dynamic interplay underscores hydralazine's suitability for intermittent rather than continuous profiles.

Adverse Effects and Risks

Hydralazine's common adverse effects stem primarily from its direct arteriolar , which triggers reflex sympathetic activation via stimulation, leading to increased and . This mechanism underlies frequent short-term reactions such as , , and , each occurring in more than 10% of patients. Flushing, , and are also prevalent, typically manifesting shortly after dosing and resolving with time or intervention. These effects exhibit dose-dependency, with higher oral doses (e.g., exceeding 100 mg daily) associated with increased incidence in clinical observations, though exact thresholds vary by individual factors like concurrent . and , in particular, may precipitate or worsen in patients with underlying due to heightened myocardial oxygen demand from sympathetic drive. Gastrointestinal symptoms like often accompany initial treatment and diminish with continued use or dose . Management typically involves dose reduction or co-administration of beta-blockers to attenuate reflex , thereby alleviating associated symptoms without compromising antihypertensive efficacy. Such adjustments are supported by data indicating reversibility upon discontinuation or modification.

Drug-Induced Lupus Erythematosus

Drug-induced lupus erythematosus (DILE) associated with hydralazine typically manifests as an autoimmune syndrome characterized by the production of autoantibodies and clinical symptoms resembling systemic lupus erythematosus (SLE), but it is generally reversible upon drug cessation. Incidence rates vary by dosage and duration, with overall estimates ranging from 5% to 20% among long-term users, though longitudinal studies indicate rates as low as 6.7% in cohorts of 281 patients. Risk escalates in a dose-dependent manner, particularly exceeding 200 mg/day, where rates can reach 10-20% after prolonged exposure (e.g., 20 years at ≥400 mg/day), and further with use beyond 6 months. Genetic predisposition plays a key role, with slow acetylators (NAT2 poor metabolizers) facing heightened susceptibility due to elevated plasma hydralazine levels, alongside associations with HLA-DRw4 phenotypes. Common symptoms include , , fever, , , (e.g., pleuritis or ), and anorexia, often developing after months to years of . Serologic hallmarks feature high-titer antinuclear antibodies (ANA), particularly anti-histone antibodies, with rare instances of anti-double-stranded DNA antibodies. Progression to severe complications like or ANCA-positive occurs infrequently but has been documented, especially in high-dose, long-term cases. Upon hydralazine discontinuation, symptoms resolve in approximately 95% of cases within 6-12 months, though immunosuppressive may accelerate recovery in instances. The pathogenic mechanism involves epigenetic dysregulation, wherein hydralazine inhibits DNA methyltransferases (DNMTs), causing global DNA hypomethylation that derepresses genes involved in , such as those promoting T-cell autoreactivity and production. This hypomethylation mimics environmental triggers in idiopathic SLE, leading to lupus-like preferentially in genetically susceptible individuals. Early clinical trials underreported DILE due to selection biases favoring shorter-term, lower-dose use and exclusion of high-risk populations like slow acetylators, underestimating the causal link in real-world, prolonged therapy scenarios.

Long-Term Safety Concerns and Contraindications

Hydralazine is contraindicated in patients with to the drug, , and mitral valvular rheumatic heart disease. In , the drug's vasodilatory effects can provoke myocardial ischemia via reflex and redistribution of coronary blood flow, potentially exacerbating the steal phenomenon in stenotic vessels. These contraindications stem from hemodynamic risks that outweigh benefits in such populations, as evidenced by clinical observations of increased and ischemic events. Long-term use of hydralazine carries risks of , particularly with high doses exceeding 200 mg daily over extended periods, manifesting as , numbness, or tingling in extremities. This , though rare (incidence <0.01% in general populations), occurs more frequently in slow acetylators due to impaired N-acetyltransferase 2 (NAT2) leading to elevated plasma concentrations and cumulative . for NAT2 variants is recommended to identify poor metabolizers, who face heightened risks and may require dose reductions or alternative therapies per pharmacogenetic guidelines. Rare instances of have been documented with chronic hydralazine exposure, involving immune-mediated destruction, often reversible upon discontinuation but necessitating hematologic monitoring in prolonged . Caution is advised in patients with active rheumatic conditions beyond involvement, as vasodilatory stress may aggravate underlying cardiac , though empirical data emphasize case-specific over blanket proscription. Overall, long-term safety hinges on individualized dosing informed by acetylator status and vigilant surveillance for neurologic and hematologic sequelae.

Drug Interactions

Pharmacodynamic Interactions

Hydralazine, as a direct arterial vasodilator, exhibits pharmacodynamic with other antihypertensive agents that lower , resulting in additive hypotensive effects. This interaction is particularly pronounced when combined with other vasodilators such as nitrates or , or with ACE inhibitors like lisinopril, where the concurrent reduction in amplifies the overall decrease in systemic . In clinical practice, such combinations necessitate careful dose to avoid excessive , though they may allow for lower individual drug doses to achieve equivalent efficacy. The reflex induced by hydralazine's is antagonized by concomitant beta-blocker therapy, such as metoprolol, which mitigates the compensatory increase in and enhances overall hemodynamic stability. This pharmacodynamic counterbalance is a rationale for triple therapy regimens incorporating hydralazine, beta-blockers, and diuretics in resistant or management. Nonsteroidal anti-inflammatory drugs (NSAIDs), including indomethacin and ibuprofen, antagonize hydralazine's antihypertensive efficacy through inhibition of synthesis, which diminishes renal and vascular -mediated essential for hydralazine's effects. Clinical data indicate this interaction can blunt reduction by up to 20-30 mmHg systolic, particularly in patients reliant on prostaglandin pathways for vascular tone regulation. Alcohol consumption potentiates hydralazine's hypotensive actions, exacerbating via additive central and peripheral effects, which can increase the risk of syncope or falls. This interaction arises from alcohol's independent depression of tone, compounding hydralazine's arteriolar relaxation without altering its . Patients are advised to limit alcohol intake during therapy to minimize these amplified postural symptoms.

Pharmacokinetic Interactions

Hydralazine demonstrates limited pharmacokinetic drug interactions, primarily due to its metabolism via by N-acetyltransferase 2 (NAT2) and hydroxylation followed by glucuronidation, with minimal involvement. Competition for NAT2 with other substrates, such as isoniazid, can theoretically increase hydralazine exposure in slow acetylators by saturating acetylation pathways, though clinical data on magnitude remain sparse. Hepatic impairment substantially reduces hydralazine clearance, as liver accounts for a significant portion despite predominant extrahepatic elimination (55-70% depending on acetylator status), resulting in elevated plasma concentrations and necessitating dose reductions or close monitoring to avoid . Concomitant use with diuretics can indirectly alter hydralazine by reducing plasma volume and enhancing renal of metabolites, potentially shortening duration of action, though this effect is secondary to pharmacodynamic in volume control. Slow , determined by , leads to 2- to 3-fold higher area under the curve (AUC) and prolonged (up to 7.8 hours versus 2.2 hours in rapid acetylators), influencing dosing requirements independent of concurrent medications.

Chemistry and Formulations

Chemical Structure and Properties

Hydralazine, chemically known as 1-hydrazinophthalazine, has the molecular formula C₈H₈N₄ and a molecular weight of 160.18 g/mol. The structure consists of a phthalazine with a (-NHNH₂) attached at the 1-position, rendering the achiral with no stereocenters. The imparts reactivity, enabling interactions such as , which influences under certain conditions. Key physicochemical properties include a of 172–173 °C for the , appearing as a white to off-white crystalline powder. of the base in is limited at approximately 4.8 mg/L (22.5 °C), though the salt form improves aqueous , facilitating stable tablet formulations. The pKₐ of 6.82 (at 25 °C) indicates partial near physiological , affecting and potential reactivity in solution. Hydralazine is typically synthesized via of 1-chlorophthalazine or reduction of phthalazinone derivatives with hydrate, yielding the hydrazino product without introducing asymmetry. This process underscores the role of the hydrazino moiety in both synthesis and the compound's intrinsic reactivity profile.

Pharmaceutical Preparations

Hydralazine is formulated primarily as oral tablets in strengths of 10 mg, 25 mg, 50 mg, and 100 mg for chronic . Injectable preparations consist of a 20 mg/mL solution in 1 mL single-dose vials for intravenous or intramuscular administration in acute settings. These formulations have been available as generics since the original brand-name Apresoline was discontinued, with no current brand-name versions marketed in the United States. Oral of hydralazine averages 25-30% but exhibits marked inter-individual variability attributable to genetic polymorphisms in N-acetyltransferase activity, resulting in slow or rapid acetylator phenotypes that affect first-pass and plasma concentrations. This variability, compounded by food-induced enhancements of up to 2- to 3-fold absorption, requires clinical monitoring of response and rather than standardized extended-release formulations, which are not routinely available or approved. Intravenous administration achieves complete bioavailability, bypassing gastrointestinal and hepatic . Hydralazine hydrochloride received FDA approval on January 15, 1953, and is included on the World Health Organization's Model List of specifically for acute management of severe pregnancy-induced . Tablets and injectable powders remain stable when stored below 25°C, protected from light and moisture, without necessitating conditions.

History

Discovery and Early Development

Hydralazine, chemically known as 1-hydrazinophthalazine, was synthesized in the by researchers at Ciba laboratories during efforts to develop antimalarial agents from derivatives. Initially designated C-5968, the compound failed to exhibit the expected activity but instead produced serendipitous vasodilatory effects in preliminary pharmacological screenings. These observations redirected attention from infectious disease treatment toward potential cardiovascular applications, as the molecule demonstrated potent relaxation of arterial . Ciba filed a for hydralazine in , which was granted in following confirmation of its unique pharmacological profile. in the late 1940s revealed significant hypotensive effects, with the drug lowering by reducing peripheral in models such as and dogs, distinct from ganglionic or adrenergic blockade mechanisms employed by contemporaneous agents. These preclinical findings underscored hydralazine's direct action on vascular , prompting its evaluation as a targeted vasodilator rather than an . Early human trials for commenced in the early 1950s, building on the animal data to assess tolerability and in patients with elevated . Initial dosing revealed consistent reduction, though accompanied by reflex due to activation, establishing the foundation for its antihypertensive role prior to broader clinical adoption.

Clinical Introduction and Regulatory Approval

Hydralazine hydrochloride, marketed as Apresoline, received approval from the U.S. (FDA) on January 15, 1953, for the treatment of . This marked it as one of the earliest oral vasodilators available for managing moderate to severe , rapidly gaining adoption in clinical practice during the and 1960s as a step-down following more acute interventions. Initial clinical use focused on its potent arteriolar dilation effects, which lowered peripheral resistance, though early protocols often overlooked compensatory reflex and sodium retention, leading to recommendations for adjunctive . Reports of a lupus-like syndrome emerged contemporaneously with approval, with the first documented association in 1953 linking hydralazine to symptoms mimicking systemic (SLE), including arthralgias, fever, and positive antinuclear antibodies. Despite these signals, widespread adoption proceeded with minimal initial restrictions, as the syndrome was viewed as reversible upon discontinuation and primarily affecting slow acetylators—a genetic factor identified in 1964—allowing hydralazine to become a mainstay in regimens. By the 1970s, cumulative evidence from case series and prospective studies established a dose-dependent incidence of up to 6.7% after prolonged use, prompting FDA-mandated warnings in labeling for monitoring autoantibodies and symptoms, alongside dose reductions to below 200 mg daily to mitigate risk. This era also saw development of fixed-dose combinations, such as with beta-blockers to counteract reflex sympathetic activation, enhancing tolerability for long-term outpatient management. Hydralazine's global rollout accelerated with its inclusion on the World Health Organization's (WHO) Model List of in 1977, prioritizing it for severe , including pregnancy-induced cases in resource-constrained settings where parenteral options were limited. Its utilization peaked in the pre-1980s era, prior to the advent of like (FDA-approved in 1981), which provided smoother without prominent reflex effects, gradually supplanting hydralazine in first- and second-line protocols due to superior side-effect profiles. Early regulatory oversights regarding risk reflected limited post-marketing surveillance capabilities at the time, underscoring a transition toward more rigorous in subsequent decades.

Clinical Evidence

Key Trials and Efficacy Data

The Vasodilator-Heart Failure Trials (V-HeFT) provided key evidence for hydralazine combined with (H-ISDN) in treating with reduced . In V-HeFT I, a of 642 patients with chronic congestive conducted from 1980 to 1985, H-ISDN reduced all-cause mortality by 34% compared to over a mean follow-up of 2.3 years (25.6% mortality in H-ISDN group vs. 42.2% in ; 0.66, 95% CI 0.46-0.95, p=0.028). This benefit was observed alongside improvements in left ventricular and exercise capacity, with the combination therapy showing a 36% reduction in three-year mortality risk. In V-HeFT II, a subsequent from 1986 to 1991 involving 804 patients already on standard and , H-ISDN was compared to enalapril; while enalapril demonstrated superior mortality reduction (18% vs. 25% at two years, relative risk reduction of 28% for enalapril), H-ISDN still conferred hemodynamic benefits, including a 58% increase in and 34% reduction in systemic . These trials established H-ISDN as an effective add-on , particularly in African American patients, with relative mortality reductions of 28-34% versus or comparators in cohorts. For hypertension, meta-analyses of randomized trials indicate hydralazine achieves modest systolic blood pressure reductions of 10-15 mmHg as monotherapy or adjunct, though with higher discontinuation rates due to adverse effects compared to alternatives like beta-blockers. Efficacy is influenced by N-acetyltransferase 2 (NAT2) acetylator status; slow acetylators exhibit higher plasma hydralazine concentrations and better blood pressure control (65% response rate) than rapid acetylators (27% response rate), even at escalated doses for the latter. Cohort studies report hydralazine-induced lupus-like syndrome in 6-7% of long-term users (95% CI 3.2-10.2%), primarily after 3 years of exposure at doses exceeding 200 mg/day, underscoring dose-dependent risks alongside efficacy.

Criticisms of Evidence and Limitations

The Vasodilator-Heart Failure Trials (V-HeFT I and II), which provided key evidence for hydralazine-isosorbide dinitrate in , have been critiqued for methodological limitations including small sample sizes and reliance on post hoc analyses stratified by , particularly showing greater apparent benefits in patients that may not generalize broadly due to inherent biases in exploratory evaluations. V-HeFT II, comparing hydralazine-isosorbide to enalapril, demonstrated borderline survival advantages for the vasodilator arm in certain subsets but lacked direct head-to-head comparisons with subsequent generations of inhibitors or ARBs, leaving unresolved questions about relative inferiority in contemporary regimens incorporating guideline-directed medical . These trials, conducted in the and early with follow-up periods averaging under two years, also underrepresented long-term risks, contributing to an evidentiary gap in assessing sustained outcomes against modern, multifaceted protocols. Hydralazine-associated (DILE) appears under-detected in pivotal trials owing to short observation windows that precede the typical onset of symptoms, which can emerge after 6-24 months of exposure at doses exceeding 200 mg daily; serologic markers like ANA positivity occur in up to 50% of patients on such regimens, yet clinical registries and post-marketing report symptomatic DILE incidence of 5-10%, higher than trial rates where follow-up rarely extended beyond acute phases. This discrepancy underscores a reliance on short-term endpoints that may overlook cumulative immunologic risks, particularly in slow acetylators predisposed by NAT2 genetic variants, where adverse drug reactions including lupus-like syndromes prompt discontinuation in up to 75% of affected cases despite pharmacogenetic testing's potential to mitigate via dose adjustment—testing remains underutilized in routine practice, leading to preventable events. Additional evidentiary critiques highlight reflex as a frequent limitation, occurring in over 50% of normotensive subjects and exacerbating or in coronary disease patients, often necessitating co-administration with beta-blockers not standardized across trials. In low-risk , hydralazine's blood pressure-lowering effects versus are documented but marred by higher withdrawal rates from adverse effects compared to first-line agents like thiazides or inhibitors, with limited randomized data questioning net benefits amid safer, once-daily alternatives that avoid sympathetic stimulation. Overall, these gaps reflect an overemphasis on surrogate endpoints in older studies, warranting caution in extrapolating to diverse, long-term real-world applications.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK470296/
  2. https://go.drugbank.com/drugs/DB01275
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Hydralazine
  4. https://karger.com/ajn/article/51/10/764/41597/Genotype-Guided-Hydralazine-Therapy
  5. https://www.ncbi.nlm.nih.gov/books/NBK548580/
  6. https://www.sciencedirect.com/science/article/abs/pii/S004901721730433X
  7. https://www.drugs.com/dosage/hydralazine.html
  8. https://pubmed.ncbi.nlm.nih.gov/21896152/
  9. https://www.researchgate.net/publication/45506478_Hydralazine_for_essential_hypertension
  10. https://www.ahajournals.org/doi/10.1161/circulationaha.110.012781
  11. https://pubmed.ncbi.nlm.nih.gov/8500241/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC6676279/
  13. https://www.nejm.org/doi/full/10.1056/NEJMoa042934
  14. https://www.nejm.org/doi/full/10.1056/NEJM199108013250502
  15. https://cvpharmacology.com/vasodilator/direct
  16. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/587994
  17. https://www.cshp.ca/Site/Site/Content/News/news-items/cp-hc.aspx
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218202/
  19. https://medicalguidelines.msf.org/en/viewport/EssDr/english/hydralazine-injectable-16682780.html
  20. https://www.obgproject.com/2017/04/16/acog-guidance-emergency-treatment-severe-hypertension/
  21. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073302
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10238817/
  23. https://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00507.x
  24. https://pubmed.ncbi.nlm.nih.gov/6236822/
  25. https://pubmed.ncbi.nlm.nih.gov/9851540/
  26. https://www.sciencedirect.com/science/article/abs/pii/S0014299998007018
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC1572994/
  28. https://www.ahajournals.org/doi/10.1161/01.hyp.5.2_pt_2.i107
  29. https://reference.medscape.com/drug/apresoline-hydralazine-342400
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7606720/
  31. https://pubmed.ncbi.nlm.nih.gov/2656046/
  32. https://www.clinpgx.org/labelAnnotation/PA166356321
  33. https://link.springer.com/article/10.2165/00003088-198916020-00003
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066965/
  35. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a04eefaf-ba3c-448d-8ece-4aa9ab2e3508
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5282409/
  37. https://www.consultant360.com/articles/hydralazine-induced-lupus-are-we-vigilant
  38. https://www.cureus.com/articles/272854-drug-induced-systemic-lupus-erythematosus-a-rare-presentation-of-hydralazine-induced-lupus
  39. https://emedicine.medscape.com/article/1065086-overview
  40. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1751-7176.2011.00573.x
  41. https://files.cpicpgx.org/data/guideline/publication/hydralazine/2025/40974042.pdf
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC6707822/
  43. https://www.ochsnerjournal.org/content/20/2/187
  44. https://www.cureus.com/articles/386382-a-delayed-adverse-reaction-hydralazine-induced-lupus-after-years-of-use
  45. https://www.sciencedirect.com/science/article/abs/pii/S1568997218301629
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5532407/
  47. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
  48. https://pubmed.ncbi.nlm.nih.gov/7304442/
  49. https://www.droracle.ai/articles/367022/how-does-hydralazine-provoke-myocardial-ischemia
  50. https://www.drugs.com/disease-interactions/hydralazine.html
  51. https://www.drugs.com/sfx/hydralazine-side-effects.html
  52. https://pubmed.ncbi.nlm.nih.gov/40974042/
  53. https://www.pediatriconcall.com/drugs/hydralazine/645
  54. https://journals.sagepub.com/doi/10.1177/1074248415587969
  55. https://pubmed.ncbi.nlm.nih.gov/4401051/
  56. https://www.drugs.com/drug-interactions/hydralazine-with-ibuprofen-1253-0-1310-0.html?professional=1
  57. https://www.healthline.com/health/drugs/hydralazine-oral-tablet
  58. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/51383/all/hydrALAZINE
  59. https://www.drugs.com/interactions-check.php?drug_list=1253-0%2C1456-0&professional=1
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC9147050/
  61. https://www.medcentral.com/drugs/monograph/8662-382246/hydralazine-oral
  62. https://pubmed.ncbi.nlm.nih.gov/36150895/
  63. https://webbook.nist.gov/cgi/inchi/InChI%253D1S/C8H8N4/c9-11-8-7-4-2-1-3-6%287%295-10-12-8/h1-5H%252C9H2%252C%28H%252C11%252C12%29
  64. https://www.sciencedirect.com/topics/chemistry/hydralazine-hydrochloride
  65. https://www.guidechem.com/encyclopedia/hydralazine-dic3390.html
  66. https://www.chemicalbook.com/ProductChemicalPropertiesCB1855362_EN.htm
  67. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=493a8b7e-5bb1-4db2-91a7-77ed87864131&type=display
  68. https://www.rxlist.com/apresoline-drug.htm
  69. https://tmedweb.tulane.edu/pharmwiki/doku.php/hydralazine
  70. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51383/all/hydrALAZINE
  71. https://www.ghsupplychain.org/sites/default/files/2022-11/MNCH%2520Commodities%2520Procurement-Hydralazine.pdf
  72. https://thepharmacynewsletter.com/the-history-of-hydralazine-a-medical-perspective/
  73. https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
  74. https://www.nejm.org/doi/abs/10.1056/NEJM198806023182209
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC1442447/
  76. https://pubmed.ncbi.nlm.nih.gov/3520315/
  77. https://pubmed.ncbi.nlm.nih.gov/39522185/
  78. https://pubmed.ncbi.nlm.nih.gov/6714290/
  79. https://www.jstor.org/stable/29516209
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC2683256/
  81. https://cardiologytrials.substack.com/p/review-of-the-v-heft-ii-trial
  82. https://www.sciencedirect.com/science/article/pii/S1578219013002667
  83. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004934.pub3/abstract
Add your contribution
Related Hubs
User Avatar
No comments yet.